CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries

Cardiovascular Diabetology

Patrice Darmon¹  Jose Luis Arenas Leon²  Guillermo Dieuzeide³  Giuseppina T. Russo⁴  Fahri Bayram⁵  Tianpei Hong⁶  Ofri Mosenzon⁷  Katerina Urbancova⁸  Shinichiro Shirabe⁹  Sergio Vencio^1,10  Abdullah Alguwaihes^1,11  Timothy M. E. Davis^1,12  Kirsten T. Eriksen^1,13  Margit S. Kaltoft^1,13  Nicolai A. Rhee^1,14  Csaba Lengyel^1,15 

[1] Aix Marseille University, INSERM, INRA, C2VN, Marseille, France;Centro de Atención E Investigación Cardiovascular del Potosí, San Luis Potosí, Mexico;Centro de Atención Integral en Diabetes, Endocrinología Y Metabolismo, Chacabuco, Buenos Aires, Argentina;Department of Clinical and Experimental Medicine, Policlinico Universitario, University of Messina, Messina, Italy;Department of Endocrinology and Metabolism, Faculty of Medicine, Erciyes University, Kayseri, Turkey;Department of Endocrinology and Metabolism, Peking University Third Hospital, Beijing, China;Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Hadassah Hebrew University Hospital, PO Box 12000, 91120, Jerusalem, Israel;Diabetologická Interní Ambulance S.R.O., Ostrava, Czech Republic;H. E. C Science Clinic, Yokohama, Japan;Instituto de Ciencias Farmaceuticas, Goiânia, Goiás, Brazil;King Saud University, King Saud University Medical City, Riyadh, Kingdom of Saudi Arabia;Medical School, University of Western Australia, Fremantle Hospital, Fremantle, Australia;Novo Nordisk A/S, Søborg, Denmark;Novo Nordisk Health Care AG, Zurich, Switzerland;University of Szeged, Szeged, Hungary;

关键词: Non-interventional study;    Type 2 diabetes;    Cardiovascular disease;    Atherosclerotic cardiovascular disease;    Prevalence;    Glucagon-like peptide-1 receptor agonists;    Sodium-glucose co-transporter-2 inhibitors;   

DOI  :  10.1186/s12933-021-01344-0

来源: Springer

【 摘 要 】

BackgroundThere is a paucity of global data on cardiovascular disease (CVD) prevalence in people with type 2 diabetes (T2D). The primary objective of the CAPTURE study was to estimate the prevalence of established CVD and its management in adults with T2D across 13 countries from five continents. Additional objectives were to further characterize the study sample regarding demographics, clinical parameters and medication usage, with particular reference to blood glucose-lowering agents (GLAs: glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors) with demonstrated cardiovascular benefit in randomized intervention trials.MethodsData were collected from adults with T2D managed in primary or specialist care in Australia, China, Japan, Czech Republic, France, Hungary, Italy, Argentina, Brazil, Mexico, Israel, Kingdom of Saudi Arabia, and Turkey in 2019, using standardized methodology. CVD prevalence, weighted by diabetes prevalence in each country, was estimated for the overall CAPTURE sample and participating countries. Country-specific odds ratios for CVD prevalence were further adjusted for relevant demographic and clinical parameters.ResultsThe overall CAPTURE sample included 9823 adults with T2D (n = 4502 from primary care; n = 5321 from specialist care). The overall CAPTURE sample had median (interquartile range) diabetes duration 10.7 years (5.6–17.9 years) and glycated hemoglobin 7.3% (6.6–8.4%) [56 mmol/mol (49–68 mmol/mol)]. Overall weighted CVD and atherosclerotic CVD prevalence estimates were 34.8% (95% confidence interval [CI] 32.7–36.8) and 31.8% (95% CI 29.7–33.8%), respectively. Age, gender, and clinical parameters accounted for some of the between-country variation in CVD prevalence. GLAs with demonstrated cardiovascular benefit were used by 21.9% of participants, which was similar in participants with and without CVD: 21.5% and 22.2%, respectively.ConclusionsIn 2019, approximately one in three adults with T2D in CAPTURE had diagnosed CVD. The low use of GLAs with demonstrated cardiovascular benefit even in participants with established CVD suggested that most were not managed according to contemporary diabetes and cardiology guidelines.Study registration NCT03786406 (registered on December 20, 2018), NCT03811288 (registered on January 18, 2019).

【 授权许可】

CC BY